Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

A new CT-scan based risk score facilitates the identification of patients at risk of revision endoscopic sinus surgery due to ...

A new CT-scan-based risk score facilitates the identification of patients at risk of revision endoscopic sinus surgery due to ...

Learn more about whether Corcept Therapeutics Incorporated or Novartis AG is a better investment based on AAII's A+ Investor ...

The following is a summary of "Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal ...

Using nasal swabs to identify a child’s asthma subtype may lead to more precise medication prescribing and development of ...

The study results demonstrate the ability to improve the sense of smell with noninvasive devices in different types of users.

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

Learn more about whether Alvotech or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which ...

Among patients with previous sinus surgery for chronic rhinosinusitis with nasal polyps, the number of past surgeries did not ...

Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to ...

REYKJAVIK, Iceland, PISCATAWAY, N.J. and LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar me ...